News List

FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'

On May 19, 2023, the FDA approved Beremagene Geperpavec (B-VEC), a topical gene therapy based on the

Wang Ben's team at Zhejiang University developed fluorine-containing polymer assembly drugs to achieve chemotherapeutic-immune cascade cancer therapy

Recently, Wang's research group from the Institute of Translational Medicine of Zhejiang Univers

The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China

On March 28, 2023, Kylo-0603, a thyroxine receptor-β (THR-β) agonist drug independently developed by

China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage

On March 15, 2023, the website of the Center for Drug Review and Evaluation (CDE) of the State Medic

The world's second! FDA grants Pfizer priority review for CD3/BCMA bispecies

Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted priority review status

The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

2023 The first fluorine-containing drug was approved. 2023.01.27 Eli Lilly's Loxo Oncology annou

PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials

Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1

adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

2022.12.12, the US FDA announced the approval of Mirati Therapeutics' oral KRAS G12C inhibitor a

New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel a

HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of